Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Impact of the BCR Phenotype of Large B-cell Lymphoma on Ibrutinib Sensitivity.

Anticancer research - 1 Jul 2026

Kotkaranta Pyry, Chan Mikko, Teppo Hanna-Riikka, Kuitunen Hanne, Turpeenniemi-Hujanen Taina, Kuittinen Outi, Kuusisto Milla E L

Abstract excerpt

BACKGROUND/AIM: Large B-cell lymphoma (LBCL) is traditionally classified by cell-of-origin (COO) into germinal center B-cell (GCB) and activated B-cell (ABC) subtypes. A consensus clustering (CC) classification has proposed three metabolic/signaling subgroups: oxidative phosphorylation (Oxphos), B-cell receptor (BCR), and host-response (HR). We aimed to determine whether this novel CC classification predicts...

Topics

Join the communities discussing this publication.

Everolimus
Lymphoma, Large B-Cell, Diffuse
Oxidative Phosphorylation
Piperidines
Purines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptors, Antigen, B-Cell

Source

Identifiers

PMID: 42373252
DOI: 10.21873/anticanres.18230

Genes

BCR
BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Impact of the BCR Phenotype of Large B-cell Lymphoma on Ibrutinib Sensitivity.PMID 42373252Read ↗

Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL)Semantic proximity Read ↗

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesSemantic proximity Read ↗

Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphomaSemantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphomaSemantic proximity Read ↗

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read ↗

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell MalignanciesSemantic proximity Read ↗

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaSemantic proximity Read ↗

Transcriptomic profiling in canine B-cell lymphoma supports a synergistic effect of BTK and PI3K inhibitorsSemantic proximity Read ↗

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphomaSemantic proximity Read ↗

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.Semantic proximity Read ↗

Targeting mitochondrial respiration and the BCL2 family in MYC-associated B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.